Medical Technology & Innovations, Inc. Announces New PhotoScreener Modifications; New Style Film Will Provide the End User With a Clearer Image At a More Affordable Price.

Business Editors/Health & Medical Writers

RIVIERA BEACH, Fla.--(BW HealthWire)--March 12, 2002

Medical Technology & Innovations, Inc. (MTIV.OB), the company known for innovative medical devices and products, announced today new plans to adapt current PhotoScreeners(TM) to accept a new film format.

Two major distributors of the PhotoScreener(TM), School Health Corporation of Hanover Park, Illinois and Marco Ophthalmic, Inc. of Jacksonville, Florida, contributed to the costs of the modifications.

The PhotoScreener(TM) is a unique and patented vision-screening device and is the first portable screening device that can detect all refractive errors, media opacities (such as cataracts), anisometropia, strabismus and astigmatism. The PhotoScreener(TM) is the first device that allows vision screening to be carried out almost anywhere.

Among its features are the use of instant film, low initial cost compared to other screening devices, and ease of use. Additionally, the MTI PhotoScreener(TM) is the vision screening device preferred by community service groups such as the Lions Club and Prevent Blindness America.

"Since product introduction, we have delivered about four thousand PhotoScreeners(TM) to an eager marketplace. We were determined to find a solution to the uncertainty of the current Polaroid film situation," stated MTI Chairman and Chief Executive Officer Jeremy P. Feakins. "We received many calls from customers encouraging us to work out a solution so the PhotoScreener(TM) could accept a different type of instant film with the same high standards. During the recent reorganization filing by the Polaroid Corporation, we were informed that the type 337 film, currently used in the PhotoScreener(TM), would not be manufactured beyond the middle of this year. We simply had to find a way to keep the PhotoScreener(TM) in operation."

Mr. Feakins added: "Our engineers have successfully worked on a solution to the problem with Polaroid Corporation, and we have developed the means to modify current PhotoScreeners at our production facility. MTI is committed to providing a smooth process to our users. We very much appreciate Polaroid's contribution to the retrofit program even during their current hardship."

"We greatly appreciate the financial cooperation of our two primary distributors, Marco Ophthalmic and School Health," continued Mr. Feakins. Mr. Rob Rogers, Vice President of School Health, stated:" We are pleased to assist our business partner MTI in finding a solution to the PhotoScreener(TM)modifications. We believe that the social benefit of PhotoScreening far outweighs the commercial value and we are committed to the program"

Mr. David Marco, President of Marco Ophthalmic, added: "As a distributor of the PhotoScreener, we were eager to become involved to keep a good thing going. The PhotoScreener(TM)has a tremendous future and promises to save the eyesight of thousands of children worldwide."

During the course of its reorganization, Polaroid decided to discontinue production of unprofitable film lines, including the 337 film. According to Ed Gaffey, Senior Manager at Polaroid Corporation, "The replacement film, 667, will provide the end user a clearer image and a more affordable price. The 667 film has been in production for many years and Polaroid has no plans to discontinue production in the foreseeable future."

For details on how to return PhotoScreeners(TM) to MTI for modifications, customers are invited to call the PhotoScreener(TM) Hotline: [phone], or visit www.photoscreener.com and navigate to the `PhotoScreener(TM) Retrofit' section. Electronic registration and payment details for the modification can also be found on the website.

About MTIV

Medical Technology & Innovations, Inc. is the parent company of Steridyne Corporation and Medical Technology, Inc. In addition to the PhotoScreener (TM), the Company manufactures and distributes product lines including probe covers, sheaths, hot and cold gel packs, wound management products, temperature taking products and anti-decubitus devices.

The Company sells its products to hospitals, medical offices, nursing homes and retail outlets.

MTI has completed clinical testing of a state-of-the-art female urinary incontinence device under the medical direction of Dr. Felecia Froe, Director, UroCare for Women, LLC, located in Kansas City, MO. Dr. Froe received both her undergraduate and medical degrees from the University of Missouri, Kansas City, and is a specialist in female urinary incontinence problems.

Note: This News Release contains certain "forward-looking statements" as such term is defined in the Private Securities Litigation Reform Act of 1995 and information relating to the Company is based on the beliefs of Company management as well as assumptions made by and information currently available to Company management.

Such statements reflect the current risks, uncertainties and assumptions related to certain factors including, without limitation, competitive factors, general economic conditions, customer relations, relationships with vendors, the interest rate environment, governmental regulation and supervision, seasonality, distribution networks, product introductions and acceptance, technological change, changes in industry practices, and one-time events.

Should any one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may vary materially from those described herein.

Website: www.mten.com